[{"orgOrder":0,"company":"Enyo Pharma","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Vonafexor","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Enyo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ OrbiMed Advisors","highestDevelopmentStatusID":"5","companyTruncated":"Enyo Pharma \/ OrbiMed Advisors"}]

Find Clinical Drug Pipeline Developments & Deals for Vonafexor

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          GRx+Biosims
                          Not Confirmed
                          GRx+Biosims
                          Not Confirmed

                          Details : Financing will support the Phase 2 Alpestria-1 study and profiling of EYP001 (vonafexor), a selective NR1H4 agonist, in Autosomal Dominant Polycystic Kidney Disease (ADPKD).

                          Product Name : EYP001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 01, 2024

                          Lead Product(s) : Vonafexor

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : OrbiMed Advisors

                          Deal Size : $42.5 million

                          Deal Type : Series C Financing

                          blank